Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis

Area of Science:

• Cardiology
• Internal Medicine
• Medical Diagnostics

Background:

• Cardiac amyloidosis (CA) is an underdiagnosed cause of heart failure.
• Amyloid light-chain (AL) and amyloid transthyretin (ATTR) are the primary subtypes of CA.
• Amyloid deposits impair cardiac function through mechanical infiltration and cardiotoxicity.

Purpose of the Study:

• To highlight the importance of recognizing "red flag symptoms" for timely CA diagnosis.
• To discuss advancements in non-invasive diagnostic methods, particularly for ATTR CA.
• To review current and emerging treatment options for AL and ATTR CA.

Main Methods:

• Review of current literature on cardiac amyloidosis diagnosis and management.
• Emphasis on clinical presentation and diagnostic red flags.
• Discussion of evolving non-invasive imaging techniques and therapeutic strategies.

Main Results:

• Timely diagnosis of CA is crucial for initiating disease-modifying therapies.
• Non-biopsy diagnosis is increasingly feasible for ATTR CA with advanced imaging.
• Significant treatment advancements have improved survival rates for both AL and ATTR CA.

Conclusions:

• Cardiac amyloidosis is a treatable condition with recent diagnostic and therapeutic progress.
• Multidisciplinary team approaches are essential for managing this systemic disease.
• Increased physician awareness of CA red flags can improve patient outcomes.